Vitiligo Clinical Trial
Official title:
The Reflection of Skin Color on the Efficacy of Narrow Band UVB in Stabilization of Active Cases of Vitiligo
Vitiligo is a disease in which autoimmunity plays a major role. Multiple treatment options
are available, of which narrow-band UVB is a cornerstone, acting through immunosuppression
and repigmentation by stimulating reservoir melanocytes.
It's expected that this immunsupression is lower in darker skin types, where increased basal
melanin might act as a barrier.
Vitiligo is acquired depigmentation disorder. Several theories were hypothesized for causing
vitiligo, of which the autoimmune theory is the most accepted.
The main targets of therapy are stabilization of the disease activity through
immunosuppression, and repigmentation through stimulation of reservoir melanocytes
proliferation and migration.
Narrow band ultraviolet phototherapy (NB-UVB) remains the cornerstone treatment of vitiligo.
NB-UVB can induce both immunosuppression and repigmentation. Several factors can modulate the
efficacy of NB-UVB therapy in treatment of vitiligo cases, including patient's age, lesion
site, duration of the disease, and duration of the therapy.
The immunosuppressive function of NB-UVB was first detected in 1963 by Hanisko and Suskind,
who observed that the contact hypersensitivity response in skin sensitized to
dinitrochlorobenzene (DNCB) was reduced if skin was previously exposed to suberythemal doses
of UVB.
Present evidence suggests that UVB suppress immune system through generation of T-suppressor
cells, which inhibit the effector cells of Th1 type. It appears that UV-induced
immunosuppression depresses the function of Th1 cells and enhances the activity of Th2 cells
via cytokines such as Interleukin 10.
It's expected that this immunsupression is lower in darker skin types, where increased basal
melanin might act as a barrier. However, skin was previously divided to UVB-resistant and
UVB-sensitive (UVB-R and UVB-S) based on the contact hypersensitivity testing, regardless of
the skin type. Moreover, A study on NB-UVB phototherapy for psoriasis revealed that
photoadaptation during NB-UVB therapy Is Independent of skin type.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05298033 -
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
|
Phase 2 | |
Recruiting |
NCT05872477 -
Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas
|
Phase 2 | |
Terminated |
NCT04374435 -
Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo
|
N/A | |
Completed |
NCT04103060 -
Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
|
Phase 2 | |
Terminated |
NCT04271501 -
Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
Completed |
NCT04530344 -
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
|
Phase 3 | |
Not yet recruiting |
NCT05008887 -
Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo
|
Phase 4 | |
Terminated |
NCT02191748 -
Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo
|
Phase 2/Phase 3 | |
Completed |
NCT01382589 -
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
|
Phase 2 | |
Terminated |
NCT01262547 -
A New Micrografting Technique for Vitiligo
|
Phase 2 | |
Active, not recruiting |
NCT04971200 -
Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo
|
Early Phase 1 | |
Completed |
NCT04872257 -
Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
|
N/A | |
Completed |
NCT04547998 -
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
|
N/A | |
Not yet recruiting |
NCT04039451 -
Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
|
||
Not yet recruiting |
NCT03611348 -
Microneedling and Latanoprost in Acrofacial Vitiligo
|
Phase 2/Phase 3 | |
Recruiting |
NCT03199664 -
Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo
|
Phase 4 | |
Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
Completed |
NCT03249064 -
Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
|
N/A | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 |